The FDA granted Argenx orphan status for cusatuzumab, its treatment of acute myeloid leukemia, according to a post on the agency’s website.
Tuesday, January 15, 2019
Cerecor congenital glycosylation IIc disorder treatment gets orphan status
The FDA granted orphan designation to Cerecor’s treatment of congenital disorder of glycosylation IIc, according to a post to the agency’s website. The Fly notes that this is the third notice of an orphan designation for a Cerecor treatment posted by the FDA today.
UnitedHealth positioned to outperform in 2019, says Piper Jaffray
Piper Jaffray analyst Sarah James said there “was so much focus” on UnitedHealth’s (UNH) earnings call on its medical loss ratio, or MLR, that it pressured the stock early in the day, but she is not concerned. When accounting for adjustments and if one accounts for some Medicaid pressure, UnitedHealth had some improvement in MA or commercial, which could be positive for Humana (HUM) or Anthem (ANTM), according to James. UnitedHealth was also clear in post call conversation that Medicaid headwinds in 2018/19 were largely company specific, which James said leaves her feeling good heading into earnings from Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG). She reiterates her Overweight rating on UnitedHealth, as James sees potential for upside to her earnings estimates and believes the stock is positioned to outperform the group in 2019 as investors move to safer positions.
https://thefly.com/landingPageNews.php?id=2849155
Aslan achieved ‘impressive’ overall response rate in BTC, says Piper Jaffray
Aslan Pharmaceuticals’ varlitinib added to gemcitabine and cisplatine achieved an “impressive” overall response rate of 43.8% and disease control rate of 93.8% in the Phase Ib/II study in first-line biliary tract cancer, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Varlitinib was also well tolerated with the most common adverse events decreases in platelet and neutrophil counts, adds the analyst. The data presented last night increase his confidence in the fully-enrolled Phase III TreeTopp trial of varlitinib in second line biliary tract cancer with top-line data in the second half of 2019. He reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.
https://thefly.com/landingPageNews.php?id=2848605
Fresenius SE downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Hassan Al-Wakeel downgraded Fresenius SE to Equal Weight and lowered his price target for the shares to EUR 51 from EUR 70. Changes to German hospital pricing regulations in 2020 could negatively impact the company’s margins, Al-Wakeel tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2848607
UnitedHealth backs FY19 adj. EPS view $14.40-$14.70, consensus $14.62
https://thefly.com/landingPageNews.php?id=2848629
Ironwood price target raised to $20 from $15 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Ironwood Pharmaceuticals to $20 to reflect higher anticipated collaboration value in China and the Cyclerion spin. The analyst also expects Ironwood to beat Q4 consensus estimates. She reiterates a Buy rating on the shares.
Subscribe to:
Posts (Atom)